ReviewJournal of clinical pharmacology2016
Safety Concerns Surrounding Quinolone Use in Children.
Review in Journal of clinical pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06253715 (Shortened Regimen for Drug-susceptible TB in Children), which is not on this map. Cited by 62 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Shortened Regimen for Drug-susceptible TB in Children
Who cites it
62 citing papers in PubMed, 4 syntheses or guidelines pooled it, 125 citations in OpenAlex.
- Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses.Clinical pharmacokinetics · 2024Pooled it
- Safety of Quinolones in Children: A Systematic Review and Meta-Analysis.Paediatric drugs · 2022Pooled it
- Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Assessment of the risk of musculoskeletal adverse events associated with fluoroquinolone use in children: A meta-analysis.Medicine · 2020Pooled it
- Current Practice in the Diagnosis and Management ofJournal of Korean medical science · 2026Article
- Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers.Clinical kidney journal · 2026Article
- Otitis Externa in a Newborn After Waterbirth-A Case Report Followed by a Literature Review.Journal of clinical medicine · 2026Article
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- A comprehensive study on enrofloxacin residue depletion in five chicken breeds.Poultry science · 2026Article
- HPLC and CE Procedures for the Determination of Fluoroquinolones (2020-2025).Molecules (Basel, Switzerland) · 2026Review
- Phage-quinolone synergy: mechanisms, clinical strategies, and translational prospects.Frontiers in microbiology · 2026Review
- Influence of Mycoplasma Resistance Genes on Pediatric Mycoplasma Pneumonia Treatment and Determinants for Second-line Antimicrobial Adjustment.Combinatorial chemistry & high throughput screening · 2026Article
- Study on Baicalin Treatment ofDrug design, development and therapy · 2026Article
- Pediatric Submandibular Lymphadenitis Caused byInfection and drug resistance · 2026Article
- Efficacy and short-term safety of intravenous omadacycline as second-line therapy for macrolide- unresponsive Mycoplasma pneumoniae pneumonia in children: a retrospective cohort study.Frontiers in cellular and infection microbiology · 2026Article
- Integrative Traditional Chinese Medicine Strategies for Refractory Mycoplasma Pneumonia in Children: Clinical Challenges, Mechanisms, and Evidence-Based Insights.Infection and drug resistance · 2026Review
- Antibiotic Exposure in School Children in Tropical Environments: Impact of Dietary Habits and Potential Health Risks.Toxics · 2025Article
- Doxycycline vs levofloxacin for macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children: a real-world study from China.Italian journal of pediatrics · 2025Observational
- Management of Mycobacterium ulcerans infection (Buruli ulcer) in Australia: consensus statement.The Medical journal of Australia · 2025Article
- The Rise, Fall, and Rethink of (Fluoro)quinolones: A Quick Rundown.Pathogens (Basel, Switzerland) · 2025Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fluoroquinolones are highly effective antibiotics with many desirable pharmacokinetic and pharmacodynamic properties including high bioavailability, large volume of distribution, and a broad spectrum of antimicrobial activity. Despite their attractive profile as anti-infective agents, their use in children is limited, primarily due to safety concerns. In this review we highlight the pharmacological properties of fluoroquinolones and describe their current use in pediatrics. In addition, we provide a comprehensive assessment of the safety data associated with fluoroquinolone use in children. Although permanent or destructive arthropathy remains a significant concern, currently available data demonstrate that arthralgia and arthropathy are relatively uncommon in children and resolve following cessation of fluoroquinolone exposure without resulting in long-term sequelae. The concern for safety and risk of adverse events associated with pediatric fluoroquinolone use is likely driving the limited prescribing of this drug class in pediatrics. However, in adults, fluoroquinolones are the most commonly prescribed broad-spectrum antibiotics, resulting in the development of drug-resistant bacteria that can be challenging to treat effectively. The consequence of misuse and overuse of fluoroquinolones leading to drug resistance is a greater, but frequently overlooked, safety concern that applies to both children and adults and one that should be considered at the point of prescribing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.